Mark Wefers Bettink

Monitoring mitochondrial respiration 5 93 T0 T1 T0 T1 0 20 40 60 80 100 MitoPO 2 (mmHg) Skin mitoPO 2 T0 T1 T0 T1 -10 -8 -6 -4 -2 0 ODR (mmhg*s -1 ) Skin ODR Control LPS # T0 T1 T0 T1 -15 -10 -5 0 ODR (mmhg*s -1 ) Muscle ODR corrected for mitoPO2 # C1 C2 C1 C2 0.0 0.5 1.0 1.5 flux (normalized) Oxygraph C1 vs C2 C1 C2 C1 C2 0 100 200 300 400 Complex activity Oxygraph C1 vs C2 Control LPS T0 T1 T0 T1 0 50 100 150 MitoPO 2 (mmHg) Muscle mitoPO 2 # A B C Figure 2. Panel A: MitoPO 2 and ODR measurements in skin at T0 and T1 in the different experimental groups, ODR M-LPS (T1) vs M-TC (T1) (p=0.0093) Panel B: MitoPO 2 and ODR in muscle at T0 and T1 in the different experimental groups, mitoPO 2 M-LPS T1 versus M-TC T1 (p=0.127) and ODR decreased M-LPS T1 vs M-TC T1 (p=0.0127). Panel C: comparison of flux (normalized) between complex 1 and complex 2 corrected for protein concentration, and comparison of complex activity in the snap frozen muscle biopsy corrected for citrate synthase. TC; time control, LPS; endotoxemia with fluid resuscitation, LPS; lipopolysaccharide, ODR; mitochondrial oxygen disappearance rate. T0 and T1 are the time points of ODR measurement. Data are presented as median ± IQR, * significant difference compared to baseline measurement, # significant difference compared to time control measurement (p<0.05); (TC; 6 rats, LPS; 8 rats).